 Frank Scott
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 20 | 2023 | 284 | 7.170 |
Why?
| | Crohn Disease | 13 | 2022 | 196 | 4.440 |
Why?
| | Infliximab | 10 | 2022 | 94 | 1.680 |
Why?
| | Colitis, Ulcerative | 6 | 2021 | 105 | 1.670 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 40 | 1.620 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 646 | 1.440 |
Why?
| | Gastrointestinal Agents | 3 | 2020 | 60 | 1.430 |
Why?
| | Gastroenterology | 4 | 2023 | 159 | 1.380 |
Why?
| | Tissue Adhesions | 3 | 2021 | 26 | 1.350 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 497 | 1.200 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1140 | 1.200 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2021 | 663 | 1.080 |
Why?
| | Intestine, Small | 2 | 2021 | 122 | 1.060 |
Why?
| | Algorithms | 6 | 2020 | 1469 | 1.000 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.940 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 38 | 0.920 |
Why?
| | Azathioprine | 5 | 2021 | 49 | 0.870 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 273 | 0.840 |
Why?
| | Biological Products | 3 | 2023 | 166 | 0.830 |
Why?
| | Abdomen | 2 | 2021 | 99 | 0.830 |
Why?
| | Abdominal Abscess | 1 | 2022 | 25 | 0.800 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1481 | 0.780 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 102 | 0.760 |
Why?
| | Humans | 75 | 2023 | 114689 | 0.740 |
Why?
| | Antibodies, Viral | 2 | 2015 | 520 | 0.740 |
Why?
| | Ustekinumab | 1 | 2020 | 12 | 0.710 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 17 | 0.700 |
Why?
| | Biomedical Research | 2 | 2019 | 585 | 0.690 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 25 | 0.680 |
Why?
| | Barrett Esophagus | 4 | 2023 | 147 | 0.680 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 373 | 0.650 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 101 | 0.630 |
Why?
| | Mass Screening | 4 | 2021 | 1004 | 0.620 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 207 | 0.620 |
Why?
| | Intestinal Fistula | 1 | 2018 | 11 | 0.610 |
Why?
| | Drug Utilization | 1 | 2019 | 167 | 0.600 |
Why?
| | Colonic Diseases | 1 | 2018 | 25 | 0.600 |
Why?
| | Postoperative Complications | 2 | 2021 | 2128 | 0.600 |
Why?
| | Health Resources | 1 | 2019 | 122 | 0.590 |
Why?
| | Pericardium | 1 | 2018 | 50 | 0.590 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 544 | 0.590 |
Why?
| | Tuberculin Test | 1 | 2017 | 32 | 0.590 |
Why?
| | Models, Statistical | 2 | 2019 | 599 | 0.580 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 72 | 0.580 |
Why?
| | Time-to-Treatment | 2 | 2019 | 147 | 0.570 |
Why?
| | Biological Factors | 2 | 2023 | 35 | 0.570 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 64 | 0.550 |
Why?
| | Colorectal Neoplasms | 5 | 2022 | 615 | 0.550 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1262 | 0.540 |
Why?
| | Retrospective Studies | 21 | 2023 | 12551 | 0.540 |
Why?
| | Hospitalization | 3 | 2022 | 1752 | 0.530 |
Why?
| | Male | 39 | 2022 | 55599 | 0.500 |
Why?
| | Natalizumab | 1 | 2015 | 46 | 0.490 |
Why?
| | Aged | 26 | 2023 | 19074 | 0.480 |
Why?
| | Middle Aged | 29 | 2023 | 26737 | 0.480 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 268 | 0.480 |
Why?
| | Heart Diseases | 1 | 2018 | 331 | 0.470 |
Why?
| | Adult | 27 | 2023 | 30550 | 0.460 |
Why?
| | Models, Theoretical | 1 | 2018 | 515 | 0.450 |
Why?
| | Colonoscopy | 6 | 2022 | 204 | 0.440 |
Why?
| | Age Factors | 4 | 2020 | 2894 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 2 | 2019 | 1177 | 0.430 |
Why?
| | Lymphoma | 1 | 2014 | 177 | 0.430 |
Why?
| | Markov Chains | 3 | 2020 | 114 | 0.420 |
Why?
| | Communicable Diseases | 1 | 2014 | 129 | 0.410 |
Why?
| | Risk Factors | 15 | 2022 | 8632 | 0.410 |
Why?
| | Patient Discharge | 2 | 2023 | 772 | 0.400 |
Why?
| | Adalimumab | 3 | 2021 | 44 | 0.400 |
Why?
| | United Kingdom | 5 | 2021 | 226 | 0.390 |
Why?
| | Female | 35 | 2022 | 59511 | 0.390 |
Why?
| | Professional Competence | 1 | 2012 | 81 | 0.380 |
Why?
| | Gastroenterologists | 2 | 2022 | 18 | 0.370 |
Why?
| | Research Design | 2 | 2019 | 928 | 0.370 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 299 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 577 | 0.360 |
Why?
| | Drug Therapy, Combination | 3 | 2020 | 951 | 0.360 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.350 |
Why?
| | Research Personnel | 1 | 2012 | 149 | 0.350 |
Why?
| | Cohort Studies | 9 | 2021 | 4895 | 0.350 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 234 | 0.340 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1075 | 0.330 |
Why?
| | Pediatric Obesity | 1 | 2016 | 489 | 0.330 |
Why?
| | Quality of Life | 2 | 2021 | 2353 | 0.330 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 196 | 0.330 |
Why?
| | Skin Neoplasms | 1 | 2016 | 756 | 0.310 |
Why?
| | Adenoma | 2 | 2022 | 189 | 0.300 |
Why?
| | Electronic Health Records | 5 | 2022 | 800 | 0.300 |
Why?
| | Databases, Factual | 7 | 2018 | 1125 | 0.290 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 858 | 0.290 |
Why?
| | Mortality | 2 | 2020 | 287 | 0.280 |
Why?
| | Disease Management | 2 | 2021 | 560 | 0.280 |
Why?
| | United States | 12 | 2021 | 12183 | 0.270 |
Why?
| | Referral and Consultation | 2 | 2023 | 635 | 0.270 |
Why?
| | Aged, 80 and over | 10 | 2020 | 6347 | 0.260 |
Why?
| | Patient Acceptance of Health Care | 2 | 2022 | 681 | 0.260 |
Why?
| | Population Surveillance | 2 | 2021 | 392 | 0.260 |
Why?
| | Case-Control Studies | 8 | 2021 | 3003 | 0.250 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 501 | 0.240 |
Why?
| | Antifungal Agents | 2 | 2016 | 128 | 0.240 |
Why?
| | Recurrence | 5 | 2021 | 935 | 0.240 |
Why?
| | Obesity | 1 | 2017 | 2508 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2021 | 833 | 0.230 |
Why?
| | Adenocarcinoma | 2 | 2021 | 795 | 0.230 |
Why?
| | Incidence | 7 | 2021 | 2313 | 0.230 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 45 | 0.230 |
Why?
| | Colectomy | 2 | 2021 | 86 | 0.210 |
Why?
| | Protective Factors | 2 | 2021 | 87 | 0.210 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 16 | 0.210 |
Why?
| | Models, Economic | 2 | 2020 | 48 | 0.210 |
Why?
| | Treatment Outcome | 8 | 2021 | 9088 | 0.210 |
Why?
| | Glucocorticoids | 2 | 2018 | 532 | 0.210 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 731 | 0.200 |
Why?
| | Cellulitis | 1 | 2022 | 45 | 0.200 |
Why?
| | Odds Ratio | 4 | 2018 | 953 | 0.200 |
Why?
| | Prognosis | 3 | 2019 | 3329 | 0.190 |
Why?
| | Liver Transplantation | 2 | 2021 | 707 | 0.190 |
Why?
| | Necrosis | 1 | 2022 | 211 | 0.190 |
Why?
| | Feces | 2 | 2022 | 373 | 0.190 |
Why?
| | Logistic Models | 5 | 2018 | 1841 | 0.190 |
Why?
| | Rectal Fistula | 1 | 2021 | 21 | 0.190 |
Why?
| | Aftercare | 1 | 2023 | 186 | 0.180 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 44 | 0.180 |
Why?
| | Esophagoscopy | 2 | 2022 | 184 | 0.180 |
Why?
| | Spondylarthritis | 1 | 2021 | 36 | 0.180 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2020 | 29 | 0.180 |
Why?
| | Cystectomy | 2 | 2017 | 32 | 0.180 |
Why?
| | Utilization Review | 1 | 2020 | 34 | 0.180 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 900 | 0.170 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 91 | 0.170 |
Why?
| | Carcinoma | 1 | 2021 | 198 | 0.170 |
Why?
| | Tryptophan | 1 | 2021 | 136 | 0.170 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2540 | 0.170 |
Why?
| | Metagenomics | 1 | 2021 | 131 | 0.170 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 30 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2023 | 197 | 0.170 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 94 | 0.170 |
Why?
| | Metabolomics | 2 | 2022 | 521 | 0.170 |
Why?
| | Hospitals | 2 | 2021 | 581 | 0.170 |
Why?
| | Surveys and Questionnaires | 5 | 2021 | 4623 | 0.170 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 311 | 0.160 |
Why?
| | Deglutition Disorders | 1 | 2021 | 118 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4411 | 0.160 |
Why?
| | Chronic Disease | 2 | 2022 | 1578 | 0.160 |
Why?
| | Job Satisfaction | 1 | 2021 | 168 | 0.160 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 211 | 0.160 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 244 | 0.160 |
Why?
| | Diverticulum | 1 | 2018 | 11 | 0.150 |
Why?
| | Prevalence | 3 | 2021 | 2251 | 0.150 |
Why?
| | Health Care Costs | 1 | 2021 | 381 | 0.150 |
Why?
| | Hematemesis | 1 | 2018 | 3 | 0.150 |
Why?
| | Symptom Assessment | 2 | 2017 | 119 | 0.150 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 259 | 0.150 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 130 | 0.150 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1003 | 0.150 |
Why?
| | Intestines | 1 | 2021 | 326 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2018 | 56 | 0.150 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 22 | 0.140 |
Why?
| | Risk Assessment | 3 | 2016 | 2968 | 0.140 |
Why?
| | Fatal Outcome | 1 | 2018 | 284 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 253 | 0.140 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 13 | 0.130 |
Why?
| | Colonic Polyps | 1 | 2017 | 67 | 0.130 |
Why?
| | Neoplasms | 2 | 2023 | 2097 | 0.130 |
Why?
| | Itraconazole | 1 | 2016 | 7 | 0.130 |
Why?
| | Guideline Adherence | 1 | 2020 | 490 | 0.130 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 203 | 0.130 |
Why?
| | Budesonide | 1 | 2016 | 87 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 49 | 0.130 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 20 | 0.130 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 64 | 0.130 |
Why?
| | Cysts | 1 | 2016 | 93 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2021 | 322 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 92 | 0.120 |
Why?
| | Data Accuracy | 1 | 2015 | 48 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 121 | 0.120 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 255 | 0.120 |
Why?
| | Psoriasis | 1 | 2016 | 74 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 42 | 0.120 |
Why?
| | Polypharmacy | 1 | 2015 | 74 | 0.120 |
Why?
| | Microbiota | 1 | 2022 | 647 | 0.120 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 172 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 486 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2017 | 719 | 0.120 |
Why?
| | Cholesterol | 1 | 2016 | 367 | 0.120 |
Why?
| | Young Adult | 6 | 2019 | 10470 | 0.120 |
Why?
| | Dilatation | 1 | 2014 | 60 | 0.110 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 328 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2015 | 116 | 0.110 |
Why?
| | Streptococcal Infections | 1 | 2016 | 131 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 220 | 0.110 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 136 | 0.110 |
Why?
| | Disease Progression | 2 | 2021 | 2380 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 195 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1768 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2014 | 128 | 0.110 |
Why?
| | Foreign Bodies | 1 | 2014 | 96 | 0.110 |
Why?
| | Primary Health Care | 2 | 2022 | 1513 | 0.110 |
Why?
| | Biomarkers | 2 | 2020 | 3408 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1214 | 0.100 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 228 | 0.100 |
Why?
| | Epidemiology | 1 | 2012 | 14 | 0.100 |
Why?
| | Endoscopy | 1 | 2014 | 246 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2013 | 211 | 0.100 |
Why?
| | Adolescent | 6 | 2019 | 17848 | 0.100 |
Why?
| | Age Distribution | 1 | 2012 | 342 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 108 | 0.090 |
Why?
| | Physicians | 1 | 2019 | 772 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1796 | 0.090 |
Why?
| | Infant | 4 | 2016 | 7963 | 0.090 |
Why?
| | Veterans | 1 | 2021 | 1249 | 0.090 |
Why?
| | Child, Preschool | 4 | 2016 | 9116 | 0.090 |
Why?
| | Medicare | 3 | 2021 | 665 | 0.080 |
Why?
| | Child | 4 | 2022 | 18415 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 4410 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1815 | 0.080 |
Why?
| | Laparoscopy | 1 | 2012 | 398 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1167 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 811 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1862 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 6220 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1211 | 0.060 |
Why?
| | Regression Analysis | 2 | 2017 | 945 | 0.050 |
Why?
| | Time Factors | 3 | 2019 | 6116 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 82 | 0.050 |
Why?
| | Cost Savings | 1 | 2021 | 74 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 40 | 0.050 |
Why?
| | Documentation | 1 | 2023 | 167 | 0.050 |
Why?
| | Training Support | 1 | 2021 | 22 | 0.050 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 52 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2765 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 280 | 0.040 |
Why?
| | Perception | 1 | 2022 | 311 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 168 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 196 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 146 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 102 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 197 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 177 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 446 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 285 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 70 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 176 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 14 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 24 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 411 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 29 | 0.040 |
Why?
| | Societies, Medical | 1 | 2021 | 664 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1373 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 530 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 229 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1644 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 75 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 782 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 51 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 604 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 642 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 532 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 52 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 30 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 361 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 226 | 0.030 |
Why?
| | Bias | 1 | 2016 | 179 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 385 | 0.030 |
Why?
| | Pennsylvania | 1 | 2014 | 94 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1518 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 442 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 171 | 0.030 |
Why?
| | Anticoagulants | 1 | 2018 | 550 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 873 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2016 | 239 | 0.030 |
Why?
| | Waiting Lists | 1 | 2015 | 211 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 407 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1395 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1737 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1430 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 319 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1715 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 1727 | 0.020 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|